Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Mahdi GharaibehAli McBrideDavid S AlbertsBrian ErstadMarion SlackNimer AlsaidJ Lyle BootmanIvo AbrahamPublished in: PharmacoEconomics (2019)
At a threshold value of £30,000/QALY, CAP + GEM was found to be the only cost-effective regimen in the management of MPC in the UK.